Myelofibrosis therapies: From palliation to disease modification - myeloproliferative neoplasms 2025

In this 1-hour live webcast, Dr. Vikas Gupta, Hematologist at the Princess Margaret Cancer Centre in Toronto, reviewed Myelofibrosis (MF) and the evolution in diagnosis, treatment options and aspects of follow-up care. It is one session in the virtual myeloproliferative neoplasms (MPN) conference, Feb. 25 - 27, 2025. Myelofibrosis (MF), a form of MPN, is a rare cancer where the bone marrow makes too many of one kind of blood cell. In MF, the abnormal cells cause normal bone marrow to be replaced by scar tissue. Over time, the fibrous scar tissue makes it harder for the bone marrow to produce normal blood cells. Fortunately, research into NMPs has meant that we are seeing an evolution in treatments and management.